Naim Issa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Naim Issa has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Samy Riad
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
9 shared publications - Aleksandra Kukla
Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN
6 shared publications - Andrew Bentall
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN
5 shared publications - Byron H. Smith
Department of Quantitative Health Sciences Mayo Clinic Rochester Minnesota USA
4 shared publications - Aleksandar Denic
Division of Nephrology and Hypertension, Mayo Clinic , Rochester, MN
3 shared publications - Hatem Amer
Division of Nephrology and Hypertension Department of Medicine Mayo Clinic Rochester Minnesota USA
3 shared publications
Latest Publications
- 12 September 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (9) , e70679
Delayed Graft Function After Simultaneous Heart–Kidney Transplantation Across Heart Allocation Eras: Predictors and Impact on Kidney Graft Survival in a National Cohort
Background: Delayed graft function (DGF) is common after simultaneous heart–kidney (SHK) transplantation, yet its predictors and long‐term consequences in contemporary practice remain incompletely defined. We evaluated the incidence, determinants, and impact of DGF on kidney graft outcomes in a national SHK cohort. Methods: Using the Scientific Registry of Transplant Recipients, between 2014–2025, we identified adult SHK recipients. After exclusions, 1637 recipients were analyzed. Baseline characteristics were compared by DGF status. Multivariable logistic regression identified DGF predictors. Cox proportional hazards models assessed DGF association with death‐censored and overall kidney graft survival. Results: DGF occurred in 29.1% of recipients ( n = 477). Independent predictors of higher DGF odds included higher recipient BMI, pre‐transplant dialysis, longer cold ischemia time, and higher refitted KDRI (all p < 0.01). In the adjusted models for long‐term kidney graft outcomes, DGF was associated with higher death‐censored graft loss (HR 2.02, 95% CI 1.11–3.65; p = 0.021) and overall graft loss (HR 2.04, 95% CI 1.47–2.82; p < 0.001). DGF rates and graft outcomes did not differ by heart allocation era ( p = 0.179), and DGF was not associated with higher kidney ( p = 0.133) or heart rejection ( p = 0.848) at 1 year. Conclusion: DGF is frequent after SHK transplantation and identifies a high‐risk subgroup with substantially inferior long‐term kidney graft survival, independent of rejection and allocation era. Given the frequency of DGF and its adverse outcomes, future studies are needed to evaluate kidney‐after‐heart safety‐net utilization and post–heart‐transplant renal recovery to optimize outcomes and promote judicious kidney allocation in SHK candidates at high risk for DGF.
- 12 September 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (9) , e70679
Delayed Graft Function After Simultaneous Heart–Kidney Transplantation Across Heart Allocation Eras: Predictors and Impact on Kidney Graft Survival in a National Cohort
Background: Delayed graft function (DGF) is common after simultaneous heart–kidney (SHK) transplantation, yet its predictors and long‐term consequences in contemporary practice remain incompletely defined. We evaluated the incidence, determinants, and impact of DGF on kidney graft outcomes in a national SHK cohort. Methods: Using the Scientific Registry of Transplant Recipients, between 2014–2025, we identified adult SHK recipients. After exclusions, 1637 recipients were analyzed. Baseline characteristics were compared by DGF status. Multivariable logistic regression identified DGF predictors. Cox proportional hazards models assessed DGF association with death‐censored and overall kidney graft survival. Results: DGF occurred in 29.1% of recipients ( n = 477). Independent predictors of higher DGF odds included higher recipient BMI, pre‐transplant dialysis, longer cold ischemia time, and higher refitted KDRI (all p < 0.01). In the adjusted models for long‐term kidney graft outcomes, DGF was associated with higher death‐censored graft loss (HR 2.02, 95% CI 1.11–3.65; p = 0.021) and overall graft loss (HR 2.04, 95% CI 1.47–2.82; p < 0.001). DGF rates and graft outcomes did not differ by heart allocation era ( p = 0.179), and DGF was not associated with higher kidney ( p = 0.133) or heart rejection ( p = 0.848) at 1 year. Conclusion: DGF is frequent after SHK transplantation and identifies a high‐risk subgroup with substantially inferior long‐term kidney graft survival, independent of rejection and allocation era. Given the frequency of DGF and its adverse outcomes, future studies are needed to evaluate kidney‐after‐heart safety‐net utilization and post–heart‐transplant renal recovery to optimize outcomes and promote judicious kidney allocation in SHK candidates at high risk for DGF.
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1814-1825
Obesity in Living Kidney Donors from Risk to Ethics
Obesity is increasingly prevalent among living kidney donor candidates, presenting complex clinical, ethical, and logistical challenges. Although obesity is linked to increased post-donation hypertension, diabetes, proteinuria, and chronic kidney disease, the overall absolute risks are modest and may differ depending on metabolic health and patterns of fat distribution. Current reliance on body mass index alone fails to capture the full spectrum of obesity-related risks, leading to inconsistent donor selection practices and potential inequities. This review examines the pathophysiological mechanisms of obesity-related kidney injury and available evidence on comorbidities and postdonation outcomes related to obesity. We discuss tools for better risk stratification, such as imaging-based adiposity assessment and personalized weight management strategies, and note that some risks may remain after weight loss. Barriers such as rigid body mass index cutoffs, limited access to treatment, and lack of long-term follow-up exacerbate disparities in access to donation. We argue for a shift toward individualized, risk-based evaluation supported by multidisciplinary care. We underscore the importance of donor counseling and advocate for a comprehensive, rather than paternalistic approach to living kidney donor selection. Advancing safe and equitable living donation in the context of rising obesity rates will necessitate revised guidelines, improved access to treatment, and an ongoing commitment to donor well-being.
- 17 February 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (10) , 1814-1825
Obesity in Living Kidney Donors from Risk to Ethics
Obesity is increasingly prevalent among living kidney donor candidates, presenting complex clinical, ethical, and logistical challenges. Although obesity is linked to increased post-donation hypertension, diabetes, proteinuria, and chronic kidney disease, the overall absolute risks are modest and may differ depending on metabolic health and patterns of fat distribution. Current reliance on body mass index alone fails to capture the full spectrum of obesity-related risks, leading to inconsistent donor selection practices and potential inequities. This review examines the pathophysiological mechanisms of obesity-related kidney injury and available evidence on comorbidities and postdonation outcomes related to obesity. We discuss tools for better risk stratification, such as imaging-based adiposity assessment and personalized weight management strategies, and note that some risks may remain after weight loss. Barriers such as rigid body mass index cutoffs, limited access to treatment, and lack of long-term follow-up exacerbate disparities in access to donation. We argue for a shift toward individualized, risk-based evaluation supported by multidisciplinary care. We underscore the importance of donor counseling and advocate for a comprehensive, rather than paternalistic approach to living kidney donor selection. Advancing safe and equitable living donation in the context of rising obesity rates will necessitate revised guidelines, improved access to treatment, and an ongoing commitment to donor well-being.
- Open Access
- 7 November 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (12) , e1875
A Comprehensive Analysis on the Impact of Hypothermic Machine Perfusion and its Influence on Delayed Graft Function
Background.: Delayed graft function (DGF) in deceased-donor kidney transplantation increases morbidity, prolongs hospitalization, and increases healthcare costs. Hypothermic machine perfusion (HMP) has emerged as a promising strategy to reduce DGF; however, large-scale real-world data remain limited. Methods.: We performed a retrospective cohort analysis using the Scientific Registry of Transplant Recipients (2014–2024), including adult dialysis-dependent recipients of deceased-donor kidneys preserved using either static cold storage (SCS) or HMP. The primary outcome was DGF, defined as dialysis requirement within 7 d posttransplant. A matched-pairs analysis was conducted using kidneys from the same donor. Results.: The overall cohort included 59 859 recipients (46.8% SCS, 53.2% HMP), with 2208 matched pairs identified. In the overall cohort, HMP grafts had longer cold ischemia times and a higher kidney donor risk index. They were more frequently obtained from older and donation after circulatory death donors. Although the overall DGF incidence was higher with HMP (34.4% versus 30.9%, P < 0.001), matched-pairs analysis revealed significantly lower DGF rates with HMP (29.8% versus 36.1%, P < 0.001). Adjusted analyses identified HMP as protective against DGF (overall cohort odds ratio, 0.71; 95% confidence interval, 0.66-0.78; paired cohort OR, 0.68; 95% CI, 0.50-0.93). Additional modifiable risk factors include prolonged cold ischemia time, higher recipient body mass index, and longer dialysis duration. Conclusions.: This real-world study demonstrates that HMP is associated with a significant reduction in DGF risk in kidney transplantation compared with SCS, supporting its broader implementation and targeted management of modifiable risk factors.
- 7 November 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (12) , e1875
Open AccessA Comprehensive Analysis on the Impact of Hypothermic Machine Perfusion and its Influence on Delayed Graft Function
Background.: Delayed graft function (DGF) in deceased-donor kidney transplantation increases morbidity, prolongs hospitalization, and increases healthcare costs. Hypothermic machine perfusion (HMP) has emerged as a promising strategy to reduce DGF; however, large-scale real-world data remain limited. Methods.: We performed a retrospective cohort analysis using the Scientific Registry of Transplant Recipients (2014–2024), including adult dialysis-dependent recipients of deceased-donor kidneys preserved using either static cold storage (SCS) or HMP. The primary outcome was DGF, defined as dialysis requirement within 7 d posttransplant. A matched-pairs analysis was conducted using kidneys from the same donor. Results.: The overall cohort included 59 859 recipients (46.8% SCS, 53.2% HMP), with 2208 matched pairs identified. In the overall cohort, HMP grafts had longer cold ischemia times and a higher kidney donor risk index. They were more frequently obtained from older and donation after circulatory death donors. Although the overall DGF incidence was higher with HMP (34.4% versus 30.9%, P < 0.001), matched-pairs analysis revealed significantly lower DGF rates with HMP (29.8% versus 36.1%, P < 0.001). Adjusted analyses identified HMP as protective against DGF (overall cohort odds ratio, 0.71; 95% confidence interval, 0.66-0.78; paired cohort OR, 0.68; 95% CI, 0.50-0.93). Additional modifiable risk factors include prolonged cold ischemia time, higher recipient body mass index, and longer dialysis duration. Conclusions.: This real-world study demonstrates that HMP is associated with a significant reduction in DGF risk in kidney transplantation compared with SCS, supporting its broader implementation and targeted management of modifiable risk factors.
- Open Access
- 8 October 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (11) , e1866
Screening Using Chronic Kidney Disease Epidemiology Collaboration 2021 Equation Glomerular Filtration Rate Underestimates in Living Kidney Donors Compared With Measurement of Glomerular Filtration Rate
Background.: Living kidney donation (KD) evaluation particularly focuses on glomerular filtration rate (GFR). Assessing GFR in living kidney donors can be done by estimation (eGFR) or measurement (mGFR). This study aims to evaluate the impact of eGFR equations, focusing on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation for donor eligibility screening and the reclassification of donors excluded by eGFR criteria to mGFR assessments. Methods.: Retrospective, single-center observational study of 2512 kidney donors evaluated between 2011 and 2023, at the Mayo Clinic. We performed analyses and comparisons of 4 eGFR formulae and 2 mGFR methods in terms of performance, eligibility criteria according to Kidney Disease: Improving Global Outcomes guidelines/age-adjusted criteria, eligibility reclassification, and subgroup analyses. Results.: The CKD-EPI 2021 resulted in a higher percentage of patients being eligible for KD (81.4%) and achieved the highest P10 (32%–34%) and P30 (87%–88%) across all mGFR methods. When patients were deemed eligible for donation by any eGFR formula, 95% retained this status on reassessment with mGFR. Conversely, when an eGFR formula classified a patient as ineligible, this was revised to be eligible in about 90% of cases on reassessment with mGFR, with a higher reclassification rate observed when the IoCl was used instead of CrCl. Conclusions.: The CKD-EPI 2021 performs best for screening potential KD. If a KD is deemed ineligible by CKD-EPI 2021, there is a high likelihood that they will be reclassified as eligible when assessed with mGFR. This study strongly supports using mGFR in donor evaluations, especially when the eGFR does not meet the criteria to ensure equity of access to being a living donor.
- 8 October 2025
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 11 (11) , e1866
Open AccessScreening Using Chronic Kidney Disease Epidemiology Collaboration 2021 Equation Glomerular Filtration Rate Underestimates in Living Kidney Donors Compared With Measurement of Glomerular Filtration Rate
Background.: Living kidney donation (KD) evaluation particularly focuses on glomerular filtration rate (GFR). Assessing GFR in living kidney donors can be done by estimation (eGFR) or measurement (mGFR). This study aims to evaluate the impact of eGFR equations, focusing on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 equation for donor eligibility screening and the reclassification of donors excluded by eGFR criteria to mGFR assessments. Methods.: Retrospective, single-center observational study of 2512 kidney donors evaluated between 2011 and 2023, at the Mayo Clinic. We performed analyses and comparisons of 4 eGFR formulae and 2 mGFR methods in terms of performance, eligibility criteria according to Kidney Disease: Improving Global Outcomes guidelines/age-adjusted criteria, eligibility reclassification, and subgroup analyses. Results.: The CKD-EPI 2021 resulted in a higher percentage of patients being eligible for KD (81.4%) and achieved the highest P10 (32%–34%) and P30 (87%–88%) across all mGFR methods. When patients were deemed eligible for donation by any eGFR formula, 95% retained this status on reassessment with mGFR. Conversely, when an eGFR formula classified a patient as ineligible, this was revised to be eligible in about 90% of cases on reassessment with mGFR, with a higher reclassification rate observed when the IoCl was used instead of CrCl. Conclusions.: The CKD-EPI 2021 performs best for screening potential KD. If a KD is deemed ineligible by CKD-EPI 2021, there is a high likelihood that they will be reclassified as eligible when assessed with mGFR. This study strongly supports using mGFR in donor evaluations, especially when the eGFR does not meet the criteria to ensure equity of access to being a living donor.
- 30 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1432-1442
Fewer medullary pyramids in the living kidney donor are associated with graft failure in the recipient
- 30 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1432-1442
Fewer medullary pyramids in the living kidney donor are associated with graft failure in the recipient
- Open Access
- 18 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (6) , 1359-1363
Pancreas irradiation for treatment-resistant acute cellular rejection in a severely immunocompromised pancreas-after-kidney transplant recipient—case report
- 18 January 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (6) , 1359-1363
Open AccessPancreas irradiation for treatment-resistant acute cellular rejection in a severely immunocompromised pancreas-after-kidney transplant recipient—case report
- Open Access
- 25 September 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (10) , e1698
Outcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States
Background.: The impact of induction type or high-risk viral discordance on older kidney transplant recipients is unclear. Herein, we analyzed the association between induction type, viral discordance, and outcomes for older recipients. Methods.: We analyzed the Scientific Registry of Transplant Recipients standard analysis file for all primary kidney transplant recipients older than 55 y who were transplanted between 2005 and 2022. All transplants were crossmatch negative and ABO-compatible. Recipients were discharged on tacrolimus and mycophenolate ± steroids. Recipients were categorized into 3 groups by induction received: rabbit antithymocyte globulin (r-ATG; N = 51 079), interleukin-2 receptor antagonist (IL-2RA; N = 22 752), and alemtuzumab (N = 13 465). Kaplan-Meier curves were generated for recipient and graft survival, and follow-up was censored at 10 y. Mixed-effect Cox proportional hazard models examined the association between induction type, high-risk viral discordance, and outcomes of interest. Models were adjusted for pertinent recipient and donor characteristics. Results.: Induction type did not predict recipient survival in the multivariable model, whereas Epstein-Barr virus high-risk discordance predicted 14% higher mortality (1.14 [1.07-1.21], P < 0.01). In the multivariable model for death-censored graft survival, alemtuzumab, but not IL-2RA, was associated with an increased risk of graft loss (1.18 [1.06-1.29], P < 0.01) compared with r-ATG. High-risk cytomegalovirus discordance predicted 10% lower death-censored graft survival (1.10 [1.01-1.19], P < 0.02). Live donor and preemptive transplantation were favorable predictors of survival. Conclusions.: In this large cohort of older transplant recipients, alemtuzumab, but not IL-2RA, induction was associated with an increased risk of graft loss compared with r-ATG. Cytomegalovirus and Epstein-Barr virus high-risk viral discordance portended poor graft and recipient survival, respectively.
- 25 September 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (10) , e1698
Open AccessOutcomes of Older Primary Kidney Transplant Recipients by Induction Agent and High-risk Viral Discordance Status in the United States
Background.: The impact of induction type or high-risk viral discordance on older kidney transplant recipients is unclear. Herein, we analyzed the association between induction type, viral discordance, and outcomes for older recipients. Methods.: We analyzed the Scientific Registry of Transplant Recipients standard analysis file for all primary kidney transplant recipients older than 55 y who were transplanted between 2005 and 2022. All transplants were crossmatch negative and ABO-compatible. Recipients were discharged on tacrolimus and mycophenolate ± steroids. Recipients were categorized into 3 groups by induction received: rabbit antithymocyte globulin (r-ATG; N = 51 079), interleukin-2 receptor antagonist (IL-2RA; N = 22 752), and alemtuzumab (N = 13 465). Kaplan-Meier curves were generated for recipient and graft survival, and follow-up was censored at 10 y. Mixed-effect Cox proportional hazard models examined the association between induction type, high-risk viral discordance, and outcomes of interest. Models were adjusted for pertinent recipient and donor characteristics. Results.: Induction type did not predict recipient survival in the multivariable model, whereas Epstein-Barr virus high-risk discordance predicted 14% higher mortality (1.14 [1.07-1.21], P < 0.01). In the multivariable model for death-censored graft survival, alemtuzumab, but not IL-2RA, was associated with an increased risk of graft loss (1.18 [1.06-1.29], P < 0.01) compared with r-ATG. High-risk cytomegalovirus discordance predicted 10% lower death-censored graft survival (1.10 [1.01-1.19], P < 0.02). Live donor and preemptive transplantation were favorable predictors of survival. Conclusions.: In this large cohort of older transplant recipients, alemtuzumab, but not IL-2RA, induction was associated with an increased risk of graft loss compared with r-ATG. Cytomegalovirus and Epstein-Barr virus high-risk viral discordance portended poor graft and recipient survival, respectively.
- 3 October 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (10) , 1766-1768
Making a Case for the Anti-inflammatory Effects of ACE Inhibitors and Angiotensin II Receptor Blockers: Evidence From Randomized Controlled Trials
- 3 October 2022
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 97 (10) , 1766-1768
Making a Case for the Anti-inflammatory Effects of ACE Inhibitors and Angiotensin II Receptor Blockers: Evidence From Randomized Controlled Trials
- 16 May 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (8) , 1411-1416
Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study
Background: Obesity is increasingly common in kidney transplant candidates and may limit access to transplantation. Obesity and diabetes are associated with a high risk for post-transplant complications. The best approach to weight loss to facilitate active transplant listing is unknown, but bariatric surgery is rarely considered due to patient- and physician-related apprehension, among other factors. Methods: We aimed to determine the magnitude of weight loss, listing, and transplant rates in 28 candidates with a mean BMI of 44.4±4.6 kg/m2 and diabetes treated conservatively for 1 year post weight-loss consultations (group 1). Additionally, we evaluated 15 patients (group 2) who met the inclusion criteria but received bariatric intervention within the same time frame. All patients completed a multidisciplinary weight management consultation with at least 1 year of follow-up. Results: In the conservatively managed group (group 1), the mean weight at the time of initial consultation was 126.5±18.5 kg, and the mean BMI was 44.4±4.6 kg/m2. At 1 year post weight-loss consultation, the mean weight decreased by 4.4±8.2 kg to 122.9±17 kg, and the mean BMI was 43±4.8 kg/m2, with a total mean body weight decrease of 3% (P=0.01). Eighteen patients (64%) did not progress to become candidates for active listing/transplantation during the follow-up time of 4±2.9 years, with 15 (54%) subsequently developing renal failure/diabetes-related comorbidities prohibitive for transplantation. In contrast, mean total body weight decreased by 19% at 6 months post bariatric surgery, and the mean BMI was 34.2±4 and 32.5±3.7 kg/m2 at 6 and 12 months, respectively. Bariatric surgery was strongly associated with subsequent kidney transplantation (HR=8.39 [95% CI 1.71 to 41.19]; P=0.009). Conclusions: A conservative weight-loss approach involving multidisciplinary consultation was ineffective in most kidney transplant candidates with diabetes, suggesting that a more proactive approach is needed.
- 16 May 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (8) , 1411-1416
Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study
Background: Obesity is increasingly common in kidney transplant candidates and may limit access to transplantation. Obesity and diabetes are associated with a high risk for post-transplant complications. The best approach to weight loss to facilitate active transplant listing is unknown, but bariatric surgery is rarely considered due to patient- and physician-related apprehension, among other factors. Methods: We aimed to determine the magnitude of weight loss, listing, and transplant rates in 28 candidates with a mean BMI of 44.4±4.6 kg/m2 and diabetes treated conservatively for 1 year post weight-loss consultations (group 1). Additionally, we evaluated 15 patients (group 2) who met the inclusion criteria but received bariatric intervention within the same time frame. All patients completed a multidisciplinary weight management consultation with at least 1 year of follow-up. Results: In the conservatively managed group (group 1), the mean weight at the time of initial consultation was 126.5±18.5 kg, and the mean BMI was 44.4±4.6 kg/m2. At 1 year post weight-loss consultation, the mean weight decreased by 4.4±8.2 kg to 122.9±17 kg, and the mean BMI was 43±4.8 kg/m2, with a total mean body weight decrease of 3% (P=0.01). Eighteen patients (64%) did not progress to become candidates for active listing/transplantation during the follow-up time of 4±2.9 years, with 15 (54%) subsequently developing renal failure/diabetes-related comorbidities prohibitive for transplantation. In contrast, mean total body weight decreased by 19% at 6 months post bariatric surgery, and the mean BMI was 34.2±4 and 32.5±3.7 kg/m2 at 6 and 12 months, respectively. Bariatric surgery was strongly associated with subsequent kidney transplantation (HR=8.39 [95% CI 1.71 to 41.19]; P=0.009). Conclusions: A conservative weight-loss approach involving multidisciplinary consultation was ineffective in most kidney transplant candidates with diabetes, suggesting that a more proactive approach is needed.